Phase 2b clinical

Related by string. * phase . phases . Phases . PHASE : Phase III clinical trials . Phase III trials . pivotal Phase III . ongoing Phase 1b / 2Bs . 2BD . 2B : 2B Marcus Giles . 2b SAC bunt . 2B Luis Castillo . 2B Freddy Sanchez / clinicals . CLINICAL . Clinicals : Phase III clinical . placebo controlled clinical trials . Clinical Excellence NICE * Phase 2b clinical trials . Phase 2b Clinical Trial *

Related by context. All words. (Click for frequent words.) 83 Phase 2a clinical 82 Phase IIb clinical 82 pivotal Phase III 80 Phase III clinical 80 phase IIb clinical 80 Phase 2b study 79 Phase IIa clinical 79 phase IIb 79 phase IIa clinical 78 Phase Ib 78 Phase 2b trial 77 Phase IIb 77 Phase 2b 77 Phase IIb trial 76 Phase 2a 76 Phase 1b clinical 76 Phase Ib clinical 76 Phase 2a trial 76 pivotal Phase 76 Phase III 76 phase IIa 75 Phase IIa trial 75 Phase 1b 74 Phase III pivotal 74 Phase IIa 74 Phase III clinical trials 74 Phase IIIb clinical 73 confirmatory Phase III 73 confirmatory Phase 3 72 phase 2a 72 phase IIb trial 72 APEX PD 72 placebo controlled Phase 72 multicenter Phase 72 Phase 1b trial 72 randomized Phase 71 Phase 1a clinical 71 clinical trial 71 phase Ib clinical 70 Phase Ib study 70 dose escalation trial 70 alvespimycin 70 SUCCEED trial 70 Phase 1a 70 placebo controlled Phase III 70 Phase Ib II 70 Phase IIb trials 70 Phase 2b clinical trials 69 Phase #b/#a 69 randomized Phase III 69 registrational trial 69 FOLOTYN ® 69 oral ridaforolimus 69 placebo controlled clinical 69 Phase IIIb 69 phase Ib 69 investigational drug 69 Phase IIB 69 BRIM2 69 Phase II 69 ADVANCE PD 69 relapsed refractory multiple myeloma 69 dirucotide 69 registrational 69 elotuzumab 68 Phase IIb clinical trials 68 BCX# 68 Phase Ib clinical trials 68 investigational compound 68 Phase Ia 68 Phase III trials 68 Phase IIa trials 68 glufosfamide 68 multiple ascending dose 68 dose escalation study 68 forodesine 68 randomized Phase IIb 68 PEG PAL 68 ongoing Phase 1b 68 Phase #b/#a clinical 68 multicenter Phase II 67 phase IIb study 67 dose escalation Phase 67 Phase IIa clinical trials 67 INCB# [001] 67 JAK inhibitor 67 trastuzumab DM1 T DM1 67 randomized controlled Phase 67 Phase Ib IIa 67 placebo controlled 67 tanespimycin 67 APPRAISE 67 viral kinetic 67 dose escalation clinical 67 investigational pan BCR 67 Zenvia ™ 66 IIa trial 66 Dacogen injection 66 rNAPc2 66 Amrubicin 66 multicenter clinical 66 BRIM3 66 double blinded placebo 66 PRX # 66 MIST II 66 multicenter randomized placebo controlled 66 relapsed multiple myeloma 66 HCV protease inhibitor 66 EOquin 66 EDEMA3 66 double blind placebo 66 axitinib 66 initiate Phase IIb 66 GALNS 66 PDX pralatrexate 66 Fx #A 66 PANVAC VF 66 docetaxel Taxotere R 66 preclinical 66 lomitapide 66 oral prodrug 66 clinical trials 65 randomized Phase 2b 65 Phase IIb kidney transplant 65 Investigational Device Exemption IDE 65 pharmacokinetics PK 65 LibiGel Phase III 65 NO# [002] 65 rALLy clinical trial 65 Phase III Pivotal 65 Phase III confirmatory 65 CR# vcMMAE 65 custirsen 65 Zerenex 65 HGS# 65 pharmacokinetic PK 65 ENDEAVOR IV 65 randomized placebo controlled 65 double blinded randomized 65 Cloretazine ® 65 IMPACT IMmunotherapy 65 diabetic neuropathic pain 65 placebo controlled randomized 65 IND enabling 65 Phase IIb III 65 Locteron ® 65 EOquin TM 65 Aurexis 65 evaluating tivozanib 65 multicenter Phase III 65 MEND CABG 65 Zenvia Phase III 65 European Sepsis Trial 65 blinded randomized placebo controlled 65 ALN TTR# 65 TMC# C# 65 Phase III randomized controlled 65 virus HCV protease inhibitor 65 IMGN# 65 PDE4 inhibitor 65 OncoVEX GM CSF 65 Phase 1b dose escalation 65 Pivotal Phase III 65 NGX# 65 TG MV 65 RG# [001] 65 opioid induced bowel dysfunction 65 TELCYTA 65 Phenoptin 64 Omigard 64 Pivotal Phase 64 histone deacetylase HDAC inhibitor 64 GAMMAGARD 64 Azedra 64 ELACYT 64 NP2 Enkephalin 64 assessing T DM1 64 randomized multicenter 64 lorvotuzumab mertansine 64 bicifadine 64 Phase 2b randomized 64 PFO migraine 64 subcutaneous formulation 64 pharmacokinetic PK study 64 phase III ACCLAIM 64 multicenter phase 64 Phase III placebo controlled 64 IIa clinical trial 64 Phase 2b kidney transplant 64 ACTEMRA TM 64 alvimopan 64 fostamatinib 64 Cloretazine R VNP#M 64 pivotal bioequivalence 64 Phase 2b monotherapy 64 prospective multicenter 64 AQ4N 64 ocrelizumab 64 RDEA# 64 randomized controlled multicenter 64 LUX Lung 64 Androxal TM 64 cetrorelix 64 elagolix 64 ZYBRESTAT fosbretabulin 64 ponatinib 64 teduglutide 64 BAY #-# 64 ganetespib 64 lintuzumab 64 dextromethorphan quinidine 64 dose cohorts 64 refractory gout 64 Phase #/#a 64 IL# PE#QQR 64 oral deforolimus 64 CLIRS trial 64 Azixa 64 HCD# [002] 64 XL# XL# XL# 63 sunitinib malate 63 RSD# oral 63 PHX# 63 IIa clinical 63 Corlux 63 HGS ETR1 63 IMA# 63 MEND CABG II 63 PRECiSE 63 Allovectin 7 63 talactoferrin 63 Tesetaxel 63 deforolimus 63 GetGoal Phase III 63 sapacitabine 63 R#/MEM # 63 L BLP# 63 CB2 selective receptor agonist 63 severe hypercholesterolemia 63 randomized double 63 ruxolitinib 63 brivaracetam 63 Fodosine 63 dextofisopam 63 huC# DM4 63 PRECISE trial 63 vicriviroc 63 pertuzumab 63 obatoclax 63 COMFORT II 63 PRE SURGE 63 picoplatin 63 TASKi2 63 Alocrest 63 MOZOBIL 63 tiapamil 63 peginesatide 63 blinatumomab 63 celgosivir 63 SPIRIT FIRST 63 Fibrillex TM 63 MERLIN TIMI 63 IIb clinical trial 63 CRx 63 CEQ# 63 phase IIb III 63 EDEMA4 63 KRN# 63 Proxinium TM 63 PLK1 SNALP 63 vidofludimus 63 INCB# [002] 63 Archexin 63 Phase III randomized 63 ZYBRESTAT 63 NASDAQ CXSP announced 63 PREOS R 63 phase IIIb 63 HER2 positive metastatic breast 63 relapsing remitting multiple sclerosis 63 Prostate AdenoCarcinoma Treatment 63 HspE7 63 multicenter randomized Phase 63 clinical pharmacology studies 63 PEG Interferon lambda 63 active comparator 63 lintuzumab SGN 63 palifosfamide 63 Panzem R 63 BR.# 63 Traficet EN 63 non nucleoside inhibitor 63 QLT# 63 mGluR5 negative 63 visilizumab 63 AzaSite Plus 63 Microplasmin 63 fosbretabulin 63 Ceflatonin R 63 Marqibo 63 confirmatory clinical 63 REOLYSIN ® 63 refractory metastatic colorectal cancer 63 MAGE A3 ASCI 63 PXD# 63 teriflunomide 63 investigational humanized monoclonal antibody 63 PREOS 63 masked placebo controlled 63 neratinib 62 cell lymphoma CTCL 62 OvaRex ® MAb 62 catheter occlusion 62 enzastaurin 62 Genasense ® 62 TACI Ig 62 cutaneous T cell 62 Bicifadine 62 Plicera 62 fidaxomicin Phase 3 62 vosaroxin 62 CA4P 62 tolerability 62 sulodexide 62 anticancer compound 62 initiated Phase Ib 62 metastatic castrate resistant 62 lorcaserin Phase 62 GRN#L 62 Phase III VISTA 62 TELINTRA 62 HGS ETR2 62 Phase IIIb study 62 MAP# 62 Elagolix 62 Pivotal Trial 62 LEP ETU 62 blind randomized placebo 62 REVLIMID lenalidomide 62 PEG SN# 62 belinostat 62 multicenter randomized double 62 Tanespimycin 62 investigational protease inhibitor 62 ofatumumab HuMax CD# 62 ularitide 62 EmbraceAC 62 palifosfamide Zymafos TM 62 novel histone deacetylase 62 ISIS # 62 HuMax CD4 62 Diabetic Macular Edema DME 62 PROSTVAC TM 62 metastatic HRPC 62 PS# [001] 62 IND submission 62 ACTEMRA 62 selective androgen receptor modulator 62 ToGA 62 tesmilifene 62 Initiate Phase 62 desvenlafaxine succinate 62 Asentar 62 ASA# 62 AZX# 62 neurogenic orthostatic hypotension 62 daclizumab 62 Ophena TM 62 MIVI III 62 PSN# [002] 62 pseudobulbar affect PBA 62 AEGR 62 Onalta ™ 62 Iluvien ® 62 HuMax EGFr 62 AP# [003] 62 label multicenter 62 Ixempra 62 TRANSFORMS 62 MEK inhibitor RDEA# 62 ANCHOR trial 62 initiate Phase 2b 62 seliciclib CYC# 62 Phase IIb Trial 62 AEG# 62 AeroLEF TM 62 randomized clinical 62 LE SN# 62 crizotinib PF # 62 pralatrexate injection 62 mipomersen 62 single ascending dose 62 CRMD# 62 CUSTOM III 62 hormone refractory prostate cancer 62 RGB # 62 ocular formulation 62 Mipomersen 62 Cloretazine 62 ThermoDox R 62 Dapagliflozin 62 SCH # 62 trastuzumab emtansine T DM1 62 RE SURGE 62 ofatumumab 62 Phase #b/#a trial 62 multicenter randomized controlled 62 randomized controlled 62 ALN PCS 62 LUMINATE 62 dose cohort 62 TLK# 62 Exherin TM 62 investigational oral 62 inhibitor RG# 62 mapatumumab 62 Tarceva TM 62 initiate Phase 62 Troxatyl 62 Urocidin 62 EFAPROXYN 62 multicenter prospective 62 Phase #/#a trial 62 nab paclitaxel 62 CoFactor 62 carfilzomib 62 Civacir 62 MAXY alpha 62 label dose escalation 61 octreotide implant 61 BRAF inhibitor 61 acyclovir Lauriad R 61 investigational hepatitis C 61 mertansine 61 tremelimumab 61 recurrent glioblastoma multiforme 61 Anturol TM 61 ADAGIO study 61 Dextofisopam 61 mTOR inhibitor 61 Personalized Immunotherapy 61 sodium Injection 61 hypoxia activated prodrug 61 Rezular 61 SinuNase 61 RSD# iv 61 Gabapentin GR 61 HCV SPRINT 61 initiate Phase 1b 61 SYMMETRY trial 61 CHAMPION PCI 61 dacetuzumab SGN 61 tezampanel 61 Genasense ® oblimersen 61 metastatic hormone refractory 61 mRCC 61 initiate Phase Ib 61 Augment Injectable 61 investigational antiplatelet agent 61 bardoxolone 61 MEK inhibitor 61 Phase III ALLEGRO 61 Randomized Phase 61 II Clinical Trial 61 compound INCB# 61 Amigal 61 microplasmin 61 perifosine KRX 61 ADX# 61 RELOVAIR ™ 61 evaluating REVLIMID 61 dose escalation 61 Aflibercept 61 CCR5 antagonist 61 Nasdaq PGNX today 61 cannabinor 61 Sym# 61 dependent kinase inhibitor 61 generation purine nucleoside 61 tesetaxel 61 ThermoDox ® 61 dimebon 61 Cetrorelix 61 randomized controlled clinical 61 PRT# 61 drug eluting coronary stent 61 platinum refractory 61 APTIVUS 61 GLP toxicology studies 61 MAA submission 61 Synavive 61 XL# SAR# 61 interferon gamma 1b 61 EVEREST II 61 docetaxel chemotherapy 61 lexidronam injection 61 Daclizumab 61 VEGF Trap 61 lymphoma CTCL 61 Shigamabs ® 61 ALN TTR 61 Phase 2a clinical trials 61 Phase 1b clinical trials 61 Proellex TM 61 multicenter 61 MGCD# [001] 61 R#/MEM 61 PNP inhibitor 61 Phase 61 Ostarine 61 controlled multicenter 61 lumiliximab 61 novel VDA molecule 61 Phase III Clinical Trial 61 dyskinesia PD LID 61 FavId 61 dacetuzumab 61 Dyloject TM 61 iclaprim 61 castrate resistant prostate cancer 61 LibiGel ® 61 OvaRex R 61 Phase III HEAT 61 unblinded 61 zalutumumab 61 PRTX 61 entinostat 61 refractory AML 61 TYKERB 61 albinterferon alfa 2b 61 targeted radiotherapeutic 61 TORISEL 61 multicentre randomized 61 Serdaxin ® 61 Sorafenib HCC Assessment 61 aclidinium bromide 61 velafermin 61 BLA filing 61 preclinical studies 61 LymphoStat B TM 61 Initiated Phase 61 iniparib 61 plus gemcitabine 61 Rebif ® 61 radiation sensitizer 61 Tyrima 61 pharmacodynamic PD 61 Myocet 61 tezampanel NGX# 61 Xanafide 61 prospective randomized controlled 61 KNS # 61 YONDELIS 61 voreloxin 61 cangrelor 61 sNDA submission 61 Clolar ® 61 VELCADE melphalan 61 reslizumab 61 vascular disrupting agent 61 BLA submission 61 PD LID 61 nitazoxanide 61 Phase 2b Clinical Trial 61 6R BH4 61 generation PNP inhibitor 61 ProSavin 61 oral formulation 61 Allovectin 7 R 61 ILUVIEN ® 61 Safinamide 61 sorafenib Nexavar 61 Panzem R NCD 61 IMC #B 61 PrevOnco ™ 61 Alzhemed TM 61 Aryplase 61 registrational studies 61 Factor VIIa 61 ONTARGET 61 telbivudine 61 oxymorphone ER 61 Zenvia TM 61 VNP#M 61 LCP AtorFen 61 Aurora kinase inhibitor 61 unique alkylating agent 61 midstage trials 61 huN# DM1 61 PROPEL trial 61 cancer neuroendocrine tumor 61 Pimavanserin 61 TBC# 61 Virulizin R 61 ANYARA 61 preclinical efficacy 60 NDA submission 60 Vicinium TM 60 pharmacokinetic 60 PI3K/Akt pathway inhibitor 60 dexanabinol 60 BOLDER II 60 nalbuphine ER 60 Ozarelix 60 EXPAREL ™ 60 treatment naïve genotype 60 ABSORB clinical 60 tolevamer 60 multicenter randomized 60 brentuximab vedotin SGN 60 randomized multicenter Phase III 60 DB# [003] 60 Anturol 60 ulimorelin 60 Sulonex TM 60 Pivotal Study 60 Pegasys R 60 cediranib 60 diarrhea predominant irritable 60 LymphoStat B 60 thorough QT 60 Oral NKTR 60 plus Copegus R 60 ABSORB trial 60 DASISION 60 pharmacodynamics 60 orBec 60 gemcitabine Gemzar ® 60 initiated Phase 1b 60 RSD# 60 JZP 60 liposomal formulation 60 ORENCIA ® 60 Phase III psoriasis 60 ILLUMINATE 60 investigational monoclonal antibody 60 SNT MC# 60 CYT# 60 CBLC# 60 Anturol ® 60 Parkinson disease levodopa induced 60 afatinib 60 zanolimumab 60 Azedra TM 60 aflibercept 60 eniluracil 60 leading oral taxane 60 trial evaluating PRX# 60 ecallantide 60 Veronate 60 dosing cohorts 60 OLpur TM H2H 60 Zerenex ™ 60 QNEXA 60 ONCONASE R 60 PF # [002] 60 DR Cysteamine 60 aflibercept VEGF Trap 60 GATTEX ® 60 adecatumumab 60 Xcellerated T Cells 60 subcutaneously administered 60 Fibrin Pad 60 torezolid phosphate 60 AIR CF1 60 perifosine 60 2 methoxyestradiol 60 evaluating T DM1 60 Apoptone 60 FOLFOX6 chemotherapy regimen 60 ospemifene 60 lupus nephritis 60 miconazole Lauriad ® 60 ancrod 60 CRLX# 60 refractory multiple myeloma 60 cutaneous T 60 evaluating Actimmune 60 Pharmacokinetics PK 60 TPI ASM8 60 Tarsa Therapeutics 60 allosteric modulator NAM 60 satraplatin Phase 60 Viramidine 60 cariprazine 60 BLOOM DM 60 temsirolimus 60 tramiprosate Alzhemed TM 60 cathepsin K inhibitor 60 Sulonex 60 INC# 60 sorafenib tablets 60 telaprevir VX 60 Laquinimod 60 T DM1 60 treatment naive genotype 60 PSMA ADC 60 FOLOTYN 60 histamine dihydrochloride 60 Chemophase 60 Phase III metastatic melanoma 60 nitric oxide donating prostaglandin 60 PEP# [003] 60 ZYBRESTAT TM 60 SPIRIT III 60 OMS#HP 60 TRO# 60 pradefovir 60 Sigma Tau SpA 60 Hsp# Inhibitor 60 SAR# [004] 60 GAMMAGARD LIQUID 60 T Pred 60 ZACTIMA 60 UPLYSO 60 Ocrelizumab 60 HCV RESPOND 2 60 oral calcitonin 60 pharmacokinetic studies 60 CIMZIA TM 60 THALOMID 60 elacytarabine 60 Ketotransdel 60 Nuvion 60 prospective randomized 60 eltrombopag 60 rALLy trial 60 COSIRA trial 60 ELND# 60 valopicitabine 60 Zybrestat 60 induced macular edema 60 ENDEAVOR III 60 metaglidasen 60 CORLUX 60 Tavocept 60 CONSERV 60 OHR/AVR# 60 #/#/# SciClone Pharmaceuticals 60 omacetaxine mepesuccinate 60 GSK# [002] 60 EndoTAG TM -1 60 refractory CLL 60 OXi# 60 RE LY 60 NUVIGIL 60 Annamycin 60 Biologics License Application BLA 60 vernakalant oral 60 PROVENGE sipuleucel T 60 XL# [003] 60 ENRICH trial 60 telomerase inhibitor drug 60 prospective multicenter randomized 60 Hyphanox 60 AZD# 60 metastatic castration resistant 60 candidate CRLX# 60 Quinamed 60 systemic anaplastic large 60 Triolex 60 Cimzia TM 60 blind placebo controlled 60 ZFP Therapeutic 60 rilonacept 60 metastatic CRPC 60 denufosol 60 Allovectin 7 ® 60 Clevudine 60 Medidur TM FA 60 CCX# B 60 relapsing multiple sclerosis 59 Matrix Phase 2b 59 orally bioavailable 59 Xeloda ® 59 EGS# 59 ATryn R 59 CLARITY study 59 receptor tyrosine kinase inhibitor 59 bosutinib 59 Ceflatonin 59 multicenter placebo controlled 59 Vicriviroc 59 darapladib 59 multi kinase inhibitor 59 otelixizumab 59 transcriptase inhibitor NNRTI 59 pegloticase 59 retinal vein occlusion induced 59 Amoxicillin PULSYS Phase III 59 TKB# 59 systemic RNAi therapeutic 59 Locteron 59 Phase III LibiGel 59 aldehyde dehydrogenase ALDH2 deficiency 59 HuLuc# 59 Zenvia 59 Zemiva ™ 59 blinded placebo controlled 59 RhuDex ® 59 Phase III Clinical Trials 59 ozarelix 59 Q#IR 59 Nasdaq RDEA 59 bortezomib Velcade 59 SPIRIT IV 59 Cleviprex TM clevidipine 59 Phase IIb Clinical Trial 59 ALN VSP 59 refractory Hodgkin lymphoma 59 ACAPODENE 59 evaluating RDEA# 59 NVA# 59 forodesine hydrochloride 59 overactive bladder AA# 59 TMC# [002] 59 humanized monoclonal antibody 59 methylnaltrexone 59 Nasdaq NYMX 59 Sular formulation 59 REG2 59 DermaVir Patch 59 vilazodone 59 ixabepilone 59 Intarcia 59 TOCOSOL Paclitaxel 59 IDX# 59 varespladib 59 DDP# 59 Curaxin CBLC# 59 bevacizumab Avastin ® 59 PS# DARA 59 alemtuzumab Campath 59 AIMM trial 59 ALN VSP Phase 59 polymerase inhibitor 59 Tarvacin TM 59 Nexavar sorafenib 59 Afatinib 59 AVASTIN 59 multicentre randomized double 59 prospective randomized placebo 59 Stedivaze 59 IPL# 59 drug pipeline TAFA# 59 Luveniq 59 Combination REOLYSIN R 59 EXPAREL TM 59 dose dose escalation 59 MDV# 59 3 registrational trial 59 Phase lll 59 L Annamycin 59 Phase 2a Clinical Trial 59 Aplidin R 59 ongoing Phase IIIb 59 topical formulation 59 thymalfasin 59 Diamyd ® 59 CINTREDEKIN BESUDOTOX 59 Ventavis 59 JAK2 inhibitor 59 LEUKINE 59 OMNARIS Nasal Spray 59 ITAX 59 antibody MAb 59 midstage clinical 59 XIENCE V Stent System 59 SinuNase TM 59 Targretin 59 IMPACT DCM clinical 59 TAXUS IV 59 BARACLUDE R 59 atrasentan 59 Iloperidone 59 EMPHASIS HF trial 59 cystinosis patients 59 lesinurad 59 inhaled formulation 59 Phase #/#a clinical 59 synthetic retinoid 59 Staccato loxapine 59 SUTENT 59 mCRC 59 interferon beta 1b 59 Topical Interferon Alpha 2b 59 INT# [002] 59 tasimelteon 59 Atiprimod 59 Vascular Wrap TM 59 Spiegelmer ® 59 Iluvien 59 CORT # 59 Alpharadin 59 HCV NS5B polymerase 59 Memryte 59 VA# [002] 59 ARCALYST 59 Advaxis Phase 59 RenalGuard System TM 59 metastatic sarcomas 59 VQD 59 LEVADEX 59 castration resistant prostate cancer 59 retaspimycin 59 Icatibant 59 EchoCRT 59 Tezampanel 59 davunetide intranasal AL 59 unblinding 59 oral nucleoside analogue 59 non nucleoside HCV 59 Nasdaq HALO 59 monotherapy 59 TEMSO 59 oral FTY# 59 paclitaxel eluting stent 59 AEZS 59 Ambrisentan 59 Nasdaq MAPP 59 novel oral anticoagulant 59 cetuximab Erbitux 59 Lymphoseek ® 59 Phase III registrational 59 Phase IIB clinical 59 MyVax R 59 IMC A# 59 blind randomized 59 refractory chronic lymphocytic 59 confirmatory Phase 59 abiraterone acetate 59 rindopepimut 59 BENLYSTA ® 59 Biopharmaceuticals AG 59 IRX 2 59 Nasdaq PPHM 59 carboplatin paclitaxel 59 UVIDEM 59 IMiD 59 eculizumab 59 metastatic renal cell 59 ceftaroline 59 CUSTOM II 59 Phase III Trial 59 HCV polymerase inhibitors 59 romidepsin 59 investigational compounds 59 dalbavancin 59 NASDAQ BPAX 59 AAG geldanamycin analog 59 Pharmion Corporation 59 Inhalation Solution 59 Marketing Authorization Application MAA 59 Degarelix 59 Clonicel 59 budesonide MMX 59 ISENTRESS 59 Inc. Nasdaq VVUS 59 Denufosol 59 ALN RSV# 59 Oxypurinol 59 Exherin 59 Phase III ThermoDox 59 nucleotide analog 59 ROCKET AF 59 GEM OS1 59 WX UK1 59 GEM OS2 59 acute peripheral arterial 59 PreCISe study 59 OMS# 59 Onco TCS 59 OncoVEX 59 MINDSET 59 MBP# [001] 59 refractory APL 59 Perifosine 59 immunotherapeutic agent 59 Aplidin 59 candidate XP# 59 TELINTRA R 59 low dose cytarabine 59 oral iron chelator 59 Brentuximab Vedotin SGN 59 multicenter study 59 metastatic renal cell carcinoma 59 sodium thiosulfate STS 59 budesonide foam 59 OPT CHF 59 AGGRASTAT R 59 orally administered inhibitor 59 Glufosfamide 59 AIR CF2 59 JAK1 59 postoperative ileus POI 59 tasocitinib 58 Hsp# inhibitor 58 CIMZIA TM certolizumab pegol 58 laquinimod

Back to home page